Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
281 questions in 50 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Large‐volume residual disease (LVRD) > 1 cm vs no macroscopic residual disease (NMRD) Progression‐free survival · women with advanced EOC after primary IDS Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian… (2022) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for… (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for… (2021) · Cochrane | no estimate extracted | NR | No studies |
Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for… (2021) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Outcomes · people with cancer with venous thromboembolism (VTE) Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Fondaparinux vs heparin Quality of life ‐ not reported · people with cancer with VTE Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Fondaparinux vs heparin Postphlebitic syndrome ‐ not reported · people with cancer with VTE Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Fondaparinux vs heparin Thrombocytopenia ‐ not reported · people with cancer with VTE Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs tinzaparin Outcomes · initial treatment in people with cancer with VTE Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs tinzaparin Quality of life ‐ not reported · initial treatment in people with cancer with VTE Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs tinzaparin Postphlebitic syndrome ‐ not reported · initial treatment in people with cancer with VTE Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Dalteparin vs tinzaparin Thrombocytopenia ‐ not reported · initial treatment in people with cancer with VTE Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Major bleeding ‐ not reported · people with cancer with venous thromboembolism (VTE) Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Minor bleeding ‐ not reported · people with cancer with venous thromboembolism (VTE) Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Quality of life ‐ not reported · people with cancer with venous thromboembolism (VTE) Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Postphlebitic syndrome ‐ not reported · people with cancer with venous thromboembolism (VTE) Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin vs unfractionated heparin Thrombocytopenia ‐ not reported · people with cancer with venous thromboembolism (VTE) Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Fondaparinux vs heparin Outcomes · people with cancer with VTE Anticoagulation for the initial treatment of venous thromboembolism in people with cancer (2021) · Cochrane | no estimate extracted | NR | No studies |
Bethanechol vs placebo Rate of spontaneous voiding recovery 1 week after surgery Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Suprapubic catheterisation vs intermittent self‐catheterisation Time after surgery to post‐void residual volume of urine ≤ 50 mL (days) Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Suprapubic catheterisation vs intermittent self‐catheterisation Post‐void residual urine volume (mL) at 1 month after surgery Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Suprapubic catheterisation vs intermittent self‐catheterisation Subjective urinary symptoms Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Bethanechol vs placebo Quality of life (QoL) Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Bethanechol vs placebo Time after surgery to post‐void residual volume of urine ≤ 50 mL (days) Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Bethanechol vs placebo Adverse events Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Bethanechol vs placebo Urinary tract infections in the first month after surgery Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Bethanechol vs placebo Subjective urinary symptoms Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Suprapubic catheterisation vs intermittent self‐catheterisation Rate of spontaneous voiding recovery 1 week after surgery Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Suprapubic catheterisation vs intermittent self‐catheterisation Quality of life (QoL) Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with… (2021) · Cochrane | no estimate extracted | NR | No studies |
Cediranib plus chemotherapy vs placebo plus chemotherapy Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy Specific adverse events: haemorrhage ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy Economic evaluation ‐ not measured · women with recurrent or FIGO stage IVB cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Pazopanib plus lapatinib vs lapatinib Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Pazopanib vs lapatinib Economic evaluation ‐ not measured · women with persistent, recurrent, or metastatic cervical cancer Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib… Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
iMRI image‐guided surgery vs standard surgery Adverse events · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Neuronavigation image‐guided surgery vs standard surgery Overall survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Neuronavigation image‐guided surgery vs standard surgery Progression‐free survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Neuronavigation image‐guided surgery vs standard surgery Quality of life · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
iMRI image‐guided surgery vs standard surgery Overall survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
iMRI image‐guided surgery vs standard surgery Progression‐free survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
iMRI image‐guided surgery vs standard surgery Quality of life · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
5‐ALA image‐guided surgery vs standard surgery Adverse events · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
5‐ALA image‐guided surgery vs standard surgery Overall survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
5‐ALA image‐guided surgery vs standard surgery Progression‐free survival · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
5‐ALA image‐guided surgery vs standard surgery Quality of life · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |